A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, or PH, including pulmonary arterial hypertension, or PAH, and PH associated with interstitial lung disease, or PH-ILD. Our goal is to be an industry leader in, and to enhance the lives of patients living with, PH. To accomplish this goal, we have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. We intend to maintain a scientifically rigorous and inclusive corporate culture where employees strive to bring improved therapeutic options to patients.
| Segment | 2024 | % of Total |
|---|---|---|
Chiesi Farmaceutici S.p.A And Chiesi USA, Inc. | $91M | 44% |
Revenue from sale of licenses | $91M | 44% |
Revenue from contracts with collaborators | $24M | 12% |
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 44M | 115M | 0 |
| Net Income | -156M | -57M | -180M |
| EPS | $-0.69 | $-0.25 | $-1.18 |
| Free Cash Flow | 0 | -3.5M | -159M |
| ROIC | -60.8% | -15.0% | -46.5% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 0.00 | 0.20 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -161M | -60M | -184M |
| Operating Margin | -365.1% | -52.2% | - |
| ROE | 0.0% | -122.5% | -286.5% |
| Shares Outstanding | 231M | 226M | 152M |
| Metric | |||
|---|---|---|---|
| Income Statement | |||
| Revenue | 0 | 115M | 44M |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -184M | -60M | -161M |
| Op. Margin | N/A | -52.2% | -365.1% |
| Net Income | -180M | -57M | -156M |
| Net Margin | N/A | -49.3% | -354.5% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | -46.5% | -15.0% | -60.8% |
| ROE | -286.5% | -122.5% | 0.0% |
| ROA | -57.6% | -18.0% | -74.8% |
| Cash Flow | |||
| Op. Cash Flow | -159M | -3.5M | -158M |
| Free Cash Flow | -159M | -3.5M | 0 |
| Owner Earnings | -189M | -25M | -180M |
| CapEx | 0 | 0 | 0 |
| Maint. CapEx | 1.6M | 833K | 833K |
| Growth CapEx | N/A | N/A | 0 |
| D&A | 1.6M | 833K | 833K |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 29M | 21M | 21M |
| Debt Repayment | 12M | 13M | 13M |
| Balance Sheet | |||
| Net Debt | -284M | -295M | -180M |
| Cash & Equiv. | N/A | N/A | 180M |
| Long-Term Debt | 814K | 0 | N/A |
| Debt/Equity | 0.20 | 0.00 | 0.00 |
| Interest Coverage | -13.6 | -5.2 | -5.2 |
| Equity | 63M | 29M | -82M |
| Total Assets | 312M | 315M | 209M |
| Total Liabilities | 249M | 286M | 291M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -1.2B | -1.3B | -1.3B |
| Working Capital | 255M | 265M | 265M |
| Current Assets | 307M | 310M | 310M |
| Current Liabilities | 52M | 45M | 45M |
| Per Share Data | |||
| EPS | -1.18 | -0.25 | -0.69 |
| Owner EPS | -1.24 | -0.11 | -0.78 |
| Book Value | 0.41 | 0.13 | -0.36 |
| Cash Flow/Share | -1.04 | -0.02 | -0.67 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 152.4M | 226.1M | 231.5M |
| Valuation | |||
| P/E Ratio | N/A | N/A | -0.6 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | 2.1 | 6.6 | N/A |
| Price/Sales | N/A | 1.8 | 2.1 |
| FCF Yield | -118.3% | -1.8% | N/A |
| Market Cap | 135M | 193M | 93M |
| Avg. Price | 1.27 | 0.92 | 0.40 |
| Year-End Price | 0.88 | 0.86 | 0.40 |
Gossamer Bio, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Gossamer Bio, Inc. (GOSS) has a 5-year average return on invested capital (ROIC) of -30.8%. This is below average and may indicate limited pricing power.
Gossamer Bio, Inc. (GOSS) has a market capitalization of $93M. It is classified as a small-cap stock.
Gossamer Bio, Inc. (GOSS) does not currently pay a regular dividend.
Gossamer Bio, Inc. (GOSS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Gossamer Bio, Inc. (GOSS) reported annual revenue of $115 million in its most recent fiscal year, based on SEC EDGAR filings.
Gossamer Bio, Inc. (GOSS) has a net profit margin of -49.3%. The company is currently unprofitable.
Gossamer Bio, Inc. (GOSS) generated $-3 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Gossamer Bio, Inc. (GOSS) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Gossamer Bio, Inc. (GOSS) reported earnings per share (EPS) of $-0.25 in its most recent fiscal year.
Gossamer Bio, Inc. (GOSS) has a return on equity (ROE) of -122.5%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for Gossamer Bio, Inc. (GOSS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Gossamer Bio, Inc. (GOSS) has a book value per share of $0.13, based on its most recent annual SEC filing.